董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Francisco Silva | 男 | Vice President of Research and Development, Secretary and Director | 50 | 122.71万美元 | 未持股 | 2025-09-18 |
| Lance Alstodt | 男 | Chief Executive Officer, President and Chairman of the Board | 54 | 131.46万美元 | 未持股 | 2025-09-18 |
| Nickolay Kukekov | 男 | Director | 51 | 12.50万美元 | 未持股 | 2025-09-18 |
| Patrick F. Williams | 男 | Director | 53 | 12.50万美元 | 未持股 | 2025-09-18 |
| David Rosa | 男 | Director | 61 | 12.50万美元 | 未持股 | 2025-09-18 |
| Robert E. Kristal | 男 | Chief Financial Officer | 58 | 68.38万美元 | 未持股 | 2025-09-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Francisco Silva | 男 | Vice President of Research and Development, Secretary and Director | 50 | 122.71万美元 | 未持股 | 2025-09-18 |
| Robert E. Kristal | 男 | Chief Financial Officer | 58 | 68.38万美元 | 未持股 | 2025-09-18 |
董事简历
中英对照 | 中文 | 英文- Francisco Silva
-
Francisco Silva，于2020年11月被选举为Biorestorative医疗公司秘书和董事。他曾担任Biorestorative Therapies， Inc.2012年3月至2012年6月担任Biorestorative Therapies， Inc.的研究科学家。2012年6月至2013年3月担任首席科学家。从2007年到2011年，他担任DV Biologics LLC的首席执行官，以及DaVinci Biosciences， LLC的总裁，DaVinci Biosciences， LLC从事人类生物制剂的商业化研究和治疗应用。从2003年到2007年，他担任PrimeGen Biotech LLC（一家从事基于细胞的平台开发的公司）的研发副总裁。从2002年到2003年，他是PrimeGen Biotech的研究科学家，负责实验设计的开发，专注于生殖系重编程干细胞平台。他曾在California State Polytechnic大学教授生物学、解剖学和高级组织培养课程。他获得了许多与干细胞相关的专利，并发表了许多关于干细胞研究的文章。他毕业于California State Polytechni大学，获得生物学学位。他还获得了California State Polytechni大学的Graduate Presidential奖学金和MBRS奖学金。
Francisco Silva was elected Biorestorative Therapies, Inc. Secretary and a director in November 2020. He served as Biorestorative Therapies, Inc. Research Scientist from March 2012 to June 2012 and as Biorestorative Therapies, Inc. Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applictions. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University. - Francisco Silva，于2020年11月被选举为Biorestorative医疗公司秘书和董事。他曾担任Biorestorative Therapies， Inc.2012年3月至2012年6月担任Biorestorative Therapies， Inc.的研究科学家。2012年6月至2013年3月担任首席科学家。从2007年到2011年，他担任DV Biologics LLC的首席执行官，以及DaVinci Biosciences， LLC的总裁，DaVinci Biosciences， LLC从事人类生物制剂的商业化研究和治疗应用。从2003年到2007年，他担任PrimeGen Biotech LLC（一家从事基于细胞的平台开发的公司）的研发副总裁。从2002年到2003年，他是PrimeGen Biotech的研究科学家，负责实验设计的开发，专注于生殖系重编程干细胞平台。他曾在California State Polytechnic大学教授生物学、解剖学和高级组织培养课程。他获得了许多与干细胞相关的专利，并发表了许多关于干细胞研究的文章。他毕业于California State Polytechni大学，获得生物学学位。他还获得了California State Polytechni大学的Graduate Presidential奖学金和MBRS奖学金。
- Francisco Silva was elected Biorestorative Therapies, Inc. Secretary and a director in November 2020. He served as Biorestorative Therapies, Inc. Research Scientist from March 2012 to June 2012 and as Biorestorative Therapies, Inc. Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applictions. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.
- Lance Alstodt
-
Lance Alstodt自2020年11月起担任我们的首席执行官，总裁兼董事会主席。他于2018年10月至2020年2月担任我们的执行副总裁兼首席战略官。自2013年以来，Alstodt先生一直担任Medvest Consulting Corporation的首席执行官，这是一家专注于医疗保健行业的咨询和资本公司。任职Medvest公司之前，他曾担任投资银行家，拥有超过23年的医疗保健投资银行经验，包括并购。从2011年到2013年，他曾担任Leerink Partners的董事总经理，在那里他曾帮助领导其医疗技术部门。从2009年到2011年，他曾担任Oppenheimer&Co.的董事总经理兼医疗技术主管。Alstodt从2000年到2009年担任Bank of America Merrill Lynch医疗保健Group和全球并购集团董事总经理。他此前曾担任J.P.Morgan Chase公司的全球并购集团的副总裁7年，在那里他曾广泛从事收购、杠杆收购、私人和公共融资、独家销售和一般咨询任务。Alstodt先生获得了纽约州立大学奥尔巴尼分校的经济学学位，次要专业是金融和营销。
Lance Alstodt,has served as Chief Executive Officer of MedVest Consulting Corporation, an advisory and capital firm that focuses exclusively on the healthcare industry. Prior to MedVest, he was an investment banker with over 23 years of experience with respect to healthcare investment banking, including mergers and acquisitions. From 2011 to 2013, Mr. Alstodt was a Managing Director at Leerink Partners where he helped lead its medical technology sector. From 2009 to 2011, he was a Managing Director and Head of Medical Technology at Oppenheimer & Co. From 2000 to 2009, Mr. Alstodt was a Managing Director in the Healthcare Group and Global Mergers and Acquisitions Group at Bank of America Merrill Lynch. He previously spent seven years as a Vice President in the Global Mergers and Acquisitions Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments. Mr. Alstodt received a degree in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing. - Lance Alstodt自2020年11月起担任我们的首席执行官，总裁兼董事会主席。他于2018年10月至2020年2月担任我们的执行副总裁兼首席战略官。自2013年以来，Alstodt先生一直担任Medvest Consulting Corporation的首席执行官，这是一家专注于医疗保健行业的咨询和资本公司。任职Medvest公司之前，他曾担任投资银行家，拥有超过23年的医疗保健投资银行经验，包括并购。从2011年到2013年，他曾担任Leerink Partners的董事总经理，在那里他曾帮助领导其医疗技术部门。从2009年到2011年，他曾担任Oppenheimer&Co.的董事总经理兼医疗技术主管。Alstodt从2000年到2009年担任Bank of America Merrill Lynch医疗保健Group和全球并购集团董事总经理。他此前曾担任J.P.Morgan Chase公司的全球并购集团的副总裁7年，在那里他曾广泛从事收购、杠杆收购、私人和公共融资、独家销售和一般咨询任务。Alstodt先生获得了纽约州立大学奥尔巴尼分校的经济学学位，次要专业是金融和营销。
- Lance Alstodt,has served as Chief Executive Officer of MedVest Consulting Corporation, an advisory and capital firm that focuses exclusively on the healthcare industry. Prior to MedVest, he was an investment banker with over 23 years of experience with respect to healthcare investment banking, including mergers and acquisitions. From 2011 to 2013, Mr. Alstodt was a Managing Director at Leerink Partners where he helped lead its medical technology sector. From 2009 to 2011, he was a Managing Director and Head of Medical Technology at Oppenheimer & Co. From 2000 to 2009, Mr. Alstodt was a Managing Director in the Healthcare Group and Global Mergers and Acquisitions Group at Bank of America Merrill Lynch. He previously spent seven years as a Vice President in the Global Mergers and Acquisitions Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments. Mr. Alstodt received a degree in Economics from the State University of New York at Albany, with a secondary concentration in Finance and Marketing.
- Nickolay Kukekov
-
Nickolay Kukekov自2021年3月起担任我们的董事之一。在过去的15年中，Kukekov博士担任过许多医疗保健投资银行职位。自2020年以来，他一直担任Paulson Investment Company，LLC的高级董事总经理。从2012年到2020年，Kukekov博士是Highline Research Advisors LLC的创始合伙人。他于2010年至2012年担任Summer Street Research Partners的董事总经理。从2007年到2009年，Kukekov博士是Paramount Capital的董事总经理。从2006年到2007年，他担任Rodmen&Renshaw的副总裁。他担任Brain Scientific，Inc.和Omnia Wellness Inc.的董事，其股票已公开交易。Kukekov博士在科罗拉多大学博尔德分校获得分子，细胞和发育生物学文学学士学位，并在哥伦比亚大学内科医生和外科医生学院获得神经科学博士学位。
Nickolay Kukekov,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons. - Nickolay Kukekov自2021年3月起担任我们的董事之一。在过去的15年中，Kukekov博士担任过许多医疗保健投资银行职位。自2020年以来，他一直担任Paulson Investment Company，LLC的高级董事总经理。从2012年到2020年，Kukekov博士是Highline Research Advisors LLC的创始合伙人。他于2010年至2012年担任Summer Street Research Partners的董事总经理。从2007年到2009年，Kukekov博士是Paramount Capital的董事总经理。从2006年到2007年，他担任Rodmen&Renshaw的副总裁。他担任Brain Scientific，Inc.和Omnia Wellness Inc.的董事，其股票已公开交易。Kukekov博士在科罗拉多大学博尔德分校获得分子，细胞和发育生物学文学学士学位，并在哥伦比亚大学内科医生和外科医生学院获得神经科学博士学位。
- Nickolay Kukekov,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons.
- Patrick F. Williams
-
Patrick F. Williams，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会审计委员会主席。威廉姆斯先生在医疗设备、消费品和技术领域拥有20多年的经验。威廉姆斯先生于2020年7月被任命为STAAR Surgical Company（“STAAR”）的首席财务官，负责优化STAAR的财务业绩，并确保各种职能的可扩展性，以支持高增长扩张。2016年至2019年，他担任Sientra公司首席财务官，之后转任miraDry 业务部门总经理。2012年至2016年，威廉姆斯担任ZELTIQ医疗公司首席财务官，该公司是一家上市医疗器械公司，被艾尔建收购。此前，他曾于2007年至2012年在NuVasive，Inc.担任财务、战略和投资者关系副总裁，这家总部位于圣迭戈的医疗设备公司为脊柱行业提供服务。他还曾在卡罗韦高尔夫和京瓷无线担任财务职务。威廉姆斯先生在圣迭戈州立大学获得金融和管理MBA学位，在加州大学圣迭戈分校获得经济学学士学位。
Patrick F. Williams,has more than 25 years of experience across medical device, consumer product goods and technology sectors. Appointed as Chief Financial Officer of NeuroPace Inc. ("NeuroPace") in June 2025, Mr. Williams is responsible for optimizing the financial performance of NeuroPace and ensuring the scalability of various functions to support high growth expansion. Mr. Williams served as Chief Financial Officer of STAAR Surgical Company from July 2020 to March 2025. From 2016 to 2019, he served as the Chief Financial Officer of Sientra, Inc. before transitioningto General Manager for its miraDry business unit. From 2012 to 2016, Mr. Williams served as Chief Financial Officer of ZELTIQ Aesthetics, Inc., a publicly-traded medical device company that was acquired by Allergan. Previously, he served as Vice President in finance, strategy and investor relations roles from 2007 to 2012 at NuVasive, Inc., a San-Diego based medical device company servicing the spine sector. He has also held finance roles with Callaway Golf and Kyocera Wireless. Mr. Williams received an MBA in Finance and Management from San Diego State University and a Bachelor of Arts in Economics from the University of California, San Diego. - Patrick F. Williams，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会审计委员会主席。威廉姆斯先生在医疗设备、消费品和技术领域拥有20多年的经验。威廉姆斯先生于2020年7月被任命为STAAR Surgical Company（“STAAR”）的首席财务官，负责优化STAAR的财务业绩，并确保各种职能的可扩展性，以支持高增长扩张。2016年至2019年，他担任Sientra公司首席财务官，之后转任miraDry 业务部门总经理。2012年至2016年，威廉姆斯担任ZELTIQ医疗公司首席财务官，该公司是一家上市医疗器械公司，被艾尔建收购。此前，他曾于2007年至2012年在NuVasive，Inc.担任财务、战略和投资者关系副总裁，这家总部位于圣迭戈的医疗设备公司为脊柱行业提供服务。他还曾在卡罗韦高尔夫和京瓷无线担任财务职务。威廉姆斯先生在圣迭戈州立大学获得金融和管理MBA学位，在加州大学圣迭戈分校获得经济学学士学位。
- Patrick F. Williams,has more than 25 years of experience across medical device, consumer product goods and technology sectors. Appointed as Chief Financial Officer of NeuroPace Inc. ("NeuroPace") in June 2025, Mr. Williams is responsible for optimizing the financial performance of NeuroPace and ensuring the scalability of various functions to support high growth expansion. Mr. Williams served as Chief Financial Officer of STAAR Surgical Company from July 2020 to March 2025. From 2016 to 2019, he served as the Chief Financial Officer of Sientra, Inc. before transitioningto General Manager for its miraDry business unit. From 2012 to 2016, Mr. Williams served as Chief Financial Officer of ZELTIQ Aesthetics, Inc., a publicly-traded medical device company that was acquired by Allergan. Previously, he served as Vice President in finance, strategy and investor relations roles from 2007 to 2012 at NuVasive, Inc., a San-Diego based medical device company servicing the spine sector. He has also held finance roles with Callaway Golf and Kyocera Wireless. Mr. Williams received an MBA in Finance and Management from San Diego State University and a Bachelor of Arts in Economics from the University of California, San Diego.
- David Rosa
-
David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
David Rosa,served as the chief executive officer and president of Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company. From 2008 to November 2009, Mr. Rosa served as chief executive officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical, Inc. Currently, he serves as a director on the board of directors of Biotricity Inc. (Nasdaq: BTCY), BioRestorative Therapies, Inc. (Nasdaq: BRTX) and Healthcare Triangle, Inc. (Nasdaq: HCTI). Mr. Rosa holds an MBA from Duquesne University and a B.S. in Commerce and Engineering from Drexel University. - David Rosa，自2021年11月起担任Biorestorative疗法公司董事和Biorestorative医疗公司董事会提名委员会主席。Rosa先生自2017年7月起担任NeuroOne Medical技术公司（“NeuroOne”）（纳斯达克：NMTC）的首席执行官、总裁和董事，并于2016年10月至2019年12月NeuroOne，Inc.与NeuroOne合并并入NeuroOne期间担任NeuroOne，Inc.的首席执行官和董事。NeuroOne是NeuroOne的全资子公司。NeuroOne致力于为患有癫痫、帕金森病、肌张力障碍、特发性震颤、背部手术失败导致的慢性疼痛和其他相关神经系统疾病的患者提供脑电图记录、脑刺激和消融解决方案的微创和高清晰度解决方案，这些解决方案可能会改善患者的预后并降低手术成本。2009年11月至2015年11月，Rosa先生担任Sunshine Heart，Inc.，n/k/a CHF Solutions，Inc.（纳斯达克：CHFS）的首席执行官兼总裁，这是一家上市的早期医疗设备公司。从2008年到2009年11月，他担任Milksmart公司的首席执行官，该公司是一家专门为动物提供医疗设备的公司。2004年至2008年，罗萨先生在圣犹达医疗公司担任心脏外科和心脏病学全球营销副总裁。他是Biotricity Inc.（纳斯达克：BTCY）和Healthcare Triangle, Inc.（纳斯达克：HCTI）董事会的董事。罗萨先生是芬兰私营公司Neuro Event Labs的董事长，也是马里兰州贝塞斯达私营公司SYNAPS Dx的顾问委员会成员。
- David Rosa,served as the chief executive officer and president of Sunshine Heart, Inc., n/k/a Nuwellis, Inc. (Nasdaq: NUWE), a publicly-held early-stage medical device company. From 2008 to November 2009, Mr. Rosa served as chief executive officer of Milksmart, Inc., a company that specializes in medical devices for animals. From 2004 to 2008, Mr. Rosa served as the vice president of global marketing for cardiac surgery and cardiology at St. Jude Medical, Inc. Currently, he serves as a director on the board of directors of Biotricity Inc. (Nasdaq: BTCY), BioRestorative Therapies, Inc. (Nasdaq: BRTX) and Healthcare Triangle, Inc. (Nasdaq: HCTI). Mr. Rosa holds an MBA from Duquesne University and a B.S. in Commerce and Engineering from Drexel University.
- Robert E. Kristal
-
Robert E. Kristal，自2021年11月起担任Biorestorative医疗公司首席财务官。克里斯塔尔先生是一位经验丰富的华尔街和湾街专业人士，曾在投资银行的多个业务部门担任过各种管理职务。2016年至2020年，他担任H.C. Wainwright股票研究主管。Kristal先生于2013年至2016年在H.C. Wainwright和T.R. Winston提供投资银行和商业银行服务。他是一名图表金融分析师。Kristal先生在Wilfrid Laurier大学获得经济学学士学位，在温莎大学获得金融学商业学士（荣誉）学位。
Robert E. Kristal,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Captal. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons. - Robert E. Kristal，自2021年11月起担任Biorestorative医疗公司首席财务官。克里斯塔尔先生是一位经验丰富的华尔街和湾街专业人士，曾在投资银行的多个业务部门担任过各种管理职务。2016年至2020年，他担任H.C. Wainwright股票研究主管。Kristal先生于2013年至2016年在H.C. Wainwright和T.R. Winston提供投资银行和商业银行服务。他是一名图表金融分析师。Kristal先生在Wilfrid Laurier大学获得经济学学士学位，在温莎大学获得金融学商业学士（荣誉）学位。
- Robert E. Kristal,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Captal. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons.
高管简历
中英对照 | 中文 | 英文- Francisco Silva
Francisco Silva，于2020年11月被选举为Biorestorative医疗公司秘书和董事。他曾担任Biorestorative Therapies， Inc.2012年3月至2012年6月担任Biorestorative Therapies， Inc.的研究科学家。2012年6月至2013年3月担任首席科学家。从2007年到2011年，他担任DV Biologics LLC的首席执行官，以及DaVinci Biosciences， LLC的总裁，DaVinci Biosciences， LLC从事人类生物制剂的商业化研究和治疗应用。从2003年到2007年，他担任PrimeGen Biotech LLC（一家从事基于细胞的平台开发的公司）的研发副总裁。从2002年到2003年，他是PrimeGen Biotech的研究科学家，负责实验设计的开发，专注于生殖系重编程干细胞平台。他曾在California State Polytechnic大学教授生物学、解剖学和高级组织培养课程。他获得了许多与干细胞相关的专利，并发表了许多关于干细胞研究的文章。他毕业于California State Polytechni大学，获得生物学学位。他还获得了California State Polytechni大学的Graduate Presidential奖学金和MBRS奖学金。
Francisco Silva was elected Biorestorative Therapies, Inc. Secretary and a director in November 2020. He served as Biorestorative Therapies, Inc. Research Scientist from March 2012 to June 2012 and as Biorestorative Therapies, Inc. Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.- Francisco Silva，于2020年11月被选举为Biorestorative医疗公司秘书和董事。他曾担任Biorestorative Therapies， Inc.2012年3月至2012年6月担任Biorestorative Therapies， Inc.的研究科学家。2012年6月至2013年3月担任首席科学家。从2007年到2011年，他担任DV Biologics LLC的首席执行官，以及DaVinci Biosciences， LLC的总裁，DaVinci Biosciences， LLC从事人类生物制剂的商业化研究和治疗应用。从2003年到2007年，他担任PrimeGen Biotech LLC（一家从事基于细胞的平台开发的公司）的研发副总裁。从2002年到2003年，他是PrimeGen Biotech的研究科学家，负责实验设计的开发，专注于生殖系重编程干细胞平台。他曾在California State Polytechnic大学教授生物学、解剖学和高级组织培养课程。他获得了许多与干细胞相关的专利，并发表了许多关于干细胞研究的文章。他毕业于California State Polytechni大学，获得生物学学位。他还获得了California State Polytechni大学的Graduate Presidential奖学金和MBRS奖学金。
- Francisco Silva was elected Biorestorative Therapies, Inc. Secretary and a director in November 2020. He served as Biorestorative Therapies, Inc. Research Scientist from March 2012 to June 2012 and as Biorestorative Therapies, Inc. Chief Scientist from June 2012 to March 2013. From 2007 to 2011, Mr. Silva served as Chief Executive Officer of DV Biologics LLC, and as President of DaVinci Biosciences, LLC, companies engaged in the commercialization of human based biologics for both research and therapeutic applications. From 2003 to 2007, Mr. Silva served as Vice President of Research and Development for PrimeGen Biotech LLC, a company engaged in the development of cell based platforms. From 2002 to 2003, he was a Research Scientist with PrimeGen Biotech and was responsible for the development of experimental designs that focused on germ line reprogramming stem cell platforms. Mr. Silva has taught courses in biology, anatomy and advanced tissue culture at California State Polytechnic University. He has obtained a number of patents relating to stem cells and has had numerous articles published with regard to stem cell research. Mr. Silva graduated from California State Polytechnic University with a degree in Biology. He also obtained a Graduate Presidential Fellowship and MBRS Fellowship from California State Polytechnic University.
- Robert E. Kristal
Robert E. Kristal，自2021年11月起担任Biorestorative医疗公司首席财务官。克里斯塔尔先生是一位经验丰富的华尔街和湾街专业人士，曾在投资银行的多个业务部门担任过各种管理职务。2016年至2020年，他担任H.C. Wainwright股票研究主管。Kristal先生于2013年至2016年在H.C. Wainwright和T.R. Winston提供投资银行和商业银行服务。他是一名图表金融分析师。Kristal先生在Wilfrid Laurier大学获得经济学学士学位，在温莎大学获得金融学商业学士（荣誉）学位。
Robert E. Kristal,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons.- Robert E. Kristal，自2021年11月起担任Biorestorative医疗公司首席财务官。克里斯塔尔先生是一位经验丰富的华尔街和湾街专业人士，曾在投资银行的多个业务部门担任过各种管理职务。2016年至2020年，他担任H.C. Wainwright股票研究主管。Kristal先生于2013年至2016年在H.C. Wainwright和T.R. Winston提供投资银行和商业银行服务。他是一名图表金融分析师。Kristal先生在Wilfrid Laurier大学获得经济学学士学位，在温莎大学获得金融学商业学士（荣誉）学位。
- Robert E. Kristal,has held a number of healthcare investment banking positions. He has served as Senior Managing Director of Paulson Investment Company, LLC since 2020. From 2012 to 2020, Dr. Kukekov was a founding partner of Highline Research Advisors LLC. He served as a Managing Director of Summer Street Research Partners from 2010 to 2012. From 2007 to 2009, Dr. Kukekov was a Managing Director of Paramount Capital. He served as a Vice President of Rodmen & Renshaw from 2006 to 2007. He serves as a director of Brain Scientific, Inc. and Omnia Wellness Inc. whose shares are publicly traded. Dr. Kukekov received a Bachelor of Arts degree in molecular, cellular and developmental biology from the University of Colorado at Boulder and a Ph.D. in neuroscience from Columbia University College of Physicians and Surgeons.